English– tag –
-
Featured in Nikkei: NBHL–FRONTEO AI Antibody Alliance
We are pleased to share that Nikkei Online has featured the collaboration bet... -
NBHL and FRONTEO Enter PoC Research Agreement to Accelerate Antibody Drug Discovery Leveraging AI and GPCR Antibody Platforms
NBHL announced that it has entered into a Proof-of-Concept (PoC) research agr... -
NBHL to Attend BIO-EUROPE in Vienna, Austria
Dates: November 3 (Mon) – 5 (Wed), 2025 Location: Vienna, Austria (Vienna Con... -
NBHL will exhibit at BioJapan2025 (Oct. 8-10)
NBHL will exhibit at BioJapan2025 to be held at Pacifico Yokohama. Booth numb... -
NBHL to Participate in BIO Asia–Taiwan 2025
Dates: July 23 (Wed) – 27 (Sun), 2025 Location: Taipei, Taiwan（Venue: Taipei... -
NBHL to Attend BIO International Convention 2025 in Boston
Dates: June 16 (Mon) – 19 (Thu), 2025 Location: Boston, USA (Boston Conventio... -
Appointment of Director/CSO
Please be advised that the following director was elected and assumed office ... -
“Life Science x AI Frontline in Sapporo” – NBHL’s Founder and President will speak at the event.
NBHL's Founder and President, Dr. Kiyoshi Takayama, will speak at the followi... -
NBHL Founder and President will speak at the “J-Startup HOKKAIDO Selected Company Pitch and Networking Event in Tokyo”.
NBHL's Founder and President, Dr. Kiyoshi Takayama, will speak at the followi... -
Announcement of Granted Patent – World’s first substance patent for human LPA1
We are pleased to announce that the substance patent for a functional antibod...
